Healthcare • Drug Manufacturers - Specialty & Generic
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if CTOR is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
2 top institutions tracked
Sentiment: unknown
No recent insider trades detected.
Red flags: 21
19 filers reported a long position in CTOR for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | $5.7M | 8.7M | -5.3% |
| BANK OF AMERICA CORP /DE/ | $2.5M | 3.8M | Unchanged |
| VANGUARD CAPITAL MANAGEMENT LLC | $355.1K | 546.3K | +2.2% |
| UBS Group AG | $217.5K | 334.6K | +808.3% |
| GEODE CAPITAL MANAGEMENT, LLC | $159.5K | 245.4K | -7.3% |
| VANGUARD FIDUCIARY TRUST CO | $79.2K | 121.9K | Unchanged |
| IFP Advisors, Inc | $69.8K | 107.4K | Unchanged |
| CITADEL ADVISORS LLC | $58.9K | 90.6K | New |
| NORTHERN TRUST CORP | $29.7K | 45.7K | Unchanged |
| STATE STREET CORP | $27.9K | 42.9K | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.